Baker Bros. Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
|
|||||
|
2024
Q3 | $576K | Hold |
|
|||||
|
2024
Q2 | $468K | Sell |
|
|||||
|
2024
Q1 | $51.4M | Hold |
|
|||||
|
2023
Q4 | $60.7M | Sell |
|
|||||
|
2023
Q3 | $90M | Hold |
|
|||||
|
2023
Q2 | $89.5M | Hold |
|
|||||
|
2023
Q1 | $106M | Hold |
|
|||||
|
2022
Q4 | $146M | Hold |
|
|||||
|
2022
Q3 | $160M | Hold |
|
|||||
|
2022
Q2 | $134M | Hold |
|
|||||
|
2022
Q1 | $207M | Hold |
|
|||||
|
2021
Q4 | $176M | Hold |
|
|||||
|
2021
Q3 | $183M | Hold |
|
|||||
|
2021
Q2 | $201M | Hold |
|
|||||
|
2021
Q1 | $129M | Buy |
|
|||||
|
2020
Q4 | $94.6M | Hold |
|
|||||
|
2020
Q3 | $43.6M | Sell |
|
|||||
|
2020
Q2 | $65.6M | Buy |
|
|||||
|
2020
Q1 | $21.9M | Hold |
|
|||||
|
2019
Q4 | $37.8M | Sell |
|
|||||
|
2019
Q3 | $36.5M | Sell |
|
|||||
|
2019
Q2 | $54.5M | Sell |
|
|||||
|
2019
Q1 | $123M | Buy |
|
|||||
|
2018
Q4 | $122M | Hold |
|
|||||
|
2018
Q3 | $115M | Buy |
|
|||||
|
2018
Q2 | $80.3M | Hold |
|
|||||
|
2018
Q1 | $66.8M | Buy |
|
|||||
|
2017
Q4 | $68.7M | Hold |
|
|||||
|
2017
Q3 | $73.3M | Buy |
|
|||||
|
2017
Q2 | $65.1M | Hold |
|
|||||
|
2017
Q1 | $98.4M | Buy |
|
|||||
|
2016
Q4 | $69.4M | Hold |
|
|||||
|
2016
Q3 | $48.4M | Sell |
|
|||||
|
2016
Q2 | $42.6M | Hold |
|
|||||
|
2016
Q1 | $42.5M | Buy |
|
|||||
|
2015
Q4 | $147M | Buy |
|
|||||
|
2015
Q3 | $161M | Buy |
|
|||||
|
2015
Q2 | $173M | Buy |
|
|||||
|
2015
Q1 | $94.6M | Sell |
|
|||||
|
2014
Q4 | $130M | Hold |
|
|||||
|
2014
Q3 | $105M | Sell |
|
|||||
|
2014
Q2 | $139M | Buy |
|
|||||
|
2014
Q1 | $62.1M | Sell |
|
|||||
|
2013
Q4 | $50.9M | Hold |
|
|||||
|
2013
Q3 | $48.8M | Buy |
|
|||||
|
2013
Q2 | $8.62M | Buy |
|